Bone density in myasthenia gravis patients receiving long-term prednisolone therapy |
| |
Authors: | Wakata Nobuo Nemoto Hiroshi Sugimoto Hideki Nomoto Nobuatu Konno Shingo Hayashi Norihide Araki You Nakazato Atushi |
| |
Institution: | Fourth Department of Internal Medicine, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo 153-8151, Japan. waka@oha.toho-u.ac.jp |
| |
Abstract: | Osteoporosis is an adverse effect of prednisolone therapy, although no study has been conducted on myasthenia gravis patients receiving high-dose prednisolone. We measured bone density in 36 patients (26 females and 10 males) who had undergone long-term prednisolone administration, and found a decrease in bone density in 31% of female patients and osteoporosis in only 11.5% (three cases). This frequency is lower than the presumptive rate of the general population in Japan (22.6%). No osteoporosis was detected in male patients. In conclusion, prednisolone-treated patients with myasthenia gravis have an acceptable risk of bone loss if prophylactic medication is administered. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|